ArticleBMC cancer2026
Evaluation of cerebrospinal fluid human epididymis protein 4 for leptomeningeal metastasis in non-small cell lung cancer: a prospective cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDiagnosing and monitoring leptomeningeal metastasis (LM) presents a significant clinical challenge. This study evaluated cerebrospinal fluid (CSF) Human Epididymis Protein 4 (HE4) as a novel diagnostic and monitoring biomarker for LM in non-small cell lung cancer (NSCLC).
methodsA prospective cohort study enrolled 117 participants (including 61 NSCLC patients with LM and 56 controls without central nervous system malignancies) from March 2023 to December 2024. Paired CSF and serum levels of HE4, carcinoembryonic antigen (CEA), and Cytokeratin 19 Fragment (CYFRA21-1) were measured using electrochemiluminescence immunoassay. Multivariable binary logistic regression, adjusting for clinical covariates (KPS, ICP, and symptom-to-diagnosis interval), was employed to identify independent diagnostic predictors. Diagnostic performance was quantified using receiver operating characteristic (ROC) curve analysis and compared via the DeLong test. Serial CSF HE4 monitoring was performed in a subset of patients to assess treatment response.
resultsCSF HE4 levels were markedly elevated in LM patients compared to controls (median 807.00 vs. 99.35 pmol/L, P < 0.001). Multivariable logistic regression revealed that CSF HE4 was a robust, independent diagnostic factor for LM (Adjusted OR = 1.027; 95% CIs: 1.010-1.044; P = 0.001), along with the CSF-to-serum HE4 ratio (Q
conclusionCSF HE4 is a promising biomarker for the diagnosis of NSCLC related LM. For CSF HE4, its robust diagnostic performance and correlation with disease activity support its use for both initial diagnosis and therapeutic monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.